DUBLIN--(BUSINESS WIRE)--The "Global Gastrointestinal Diseases Therapeutics Market 2022-2026" report has been added to ResearchAndMarkets.com's offering.
The gastrointestinal diseases therapeutics market is poised to grow by $1.60 bn during 2022-2026, accelerating at a CAGR of 6.68%.
The market is driven by the increasing incidence of gastrointestinal diseases, new product launches, and increasing demand for biologics and targeted therapies.
This study identifies the strong product pipeline as one of the prime reasons driving the gastrointestinal diseases therapeutics market growth during the next few years. Also, funding for gastrointestinal research studies and increase in self-medication coupled with home-based therapies will lead to sizable demand in the market.
The report on the gastrointestinal diseases therapeutics market provides a holistic analysis, market size and forecast, trends, growth drivers, and challenges, as well as vendor analysis covering around 25 vendors. The report offers an up-to-date analysis of the current global market scenario, the latest trends and drivers, and the overall market environment. The gastrointestinal diseases therapeutics market analysis includes the product segment and geographic landscape.
The robust vendor analysis is designed to help clients improve their market position, and in line with this, this report provides a detailed analysis of several leading gastrointestinal diseases therapeutics market vendors. Also, the gastrointestinal diseases therapeutics market analysis report includes information on upcoming trends and challenges that will influence market growth. This is to help companies strategize and leverage all forthcoming growth opportunities.
Key Topics Covered:
1 Executive Summary
1.1 Market overview
2 Market Landscape
2.1 Market ecosystem
3 Market Sizing
3.1 Market definition
3.2 Market segment analysis
3.3 Market size 2021
3.4 Market outlook: Forecast for 2021-2026
4 Five Forces Analysis
4.1 Five forces summary
4.2 Bargaining power of buyers
4.3 Bargaining power of suppliers
4.4 Threat of new entrants
4.5 Threat of substitutes
4.6 Threat of rivalry
4.7 Market condition
5 Market Segmentation by Drug Class
5.1 Market segments
5.2 Comparison by Drug Class
5.3 Anti-inflammatory and immunosuppressors - Market size and forecast 2021-2026
5.4 Acid neutralizers - Market size and forecast 2021-2026
5.5 Other therapeutics - Market size and forecast 2021-2026
5.6 Market opportunity by Drug Class
6 Customer Landscape
6.1 Customer landscape overview
7 Geographic Landscape
7.1 Geographic segmentation
7.2 Geographic comparison
7.3 North America - Market size and forecast 2021-2026
7.4 Europe - Market size and forecast 2021-2026
7.5 Asia - Market size and forecast 2021-2026
7.6 Rest of World (ROW) - Market size and forecast 2021-2026
7.7 US - Market size and forecast 2021-2026
7.8 Japan - Market size and forecast 2021-2026
7.9 China - Market size and forecast 2021-2026
7.10 Germany - Market size and forecast 2021-2026
7.11 France - Market size and forecast 2021-2026
7.12 Market opportunity By Geographical Landscape
8 Drivers, Challenges, and Trends
8.1 Market drivers
8.2 Market challenges
8.3 Impact of drivers and challenges
8.4 Market trends
9 Vendor Landscape
9.1 Overview
9.2 Vendor landscape
9.3 Landscape disruption
9.4 Industry risks
10 Vendor Analysis
10.1 Vendors covered
10.2 Market positioning of vendors
- Abbott Laboratories
- AbbVie Inc.
- AstraZeneca Plc
- Bausch Health Co Inc
- Bayer AG
- Biogen Inc.
- Boston Scientific Corp.
- C. H. Boehringer Sohn AG and Co. KG
- Eisai Co. Ltd.
- Eli Lilly and Co.
- Evoke Pharma Inc
- GlaxoSmithKline Plc
- Johnson and Johnson
- Merck and Co. Inc.
- Novartis AG
- Olympus Corp.
- OVESCO ENDOSCOPY AG
- Pfizer Inc.
- Takeda Pharmaceutical Co. Ltd.
- UCB SA
For more information about this report visit https://www.researchandmarkets.com/r/c44z7l
